Life sciences venture capital (VC) firm Omega Funds has closed its eighth fund, with capital commitments totalling $647m.

The US Court of Appeals has overturned a $106.5m ruling wherein a California court jury found that Medtronic infringed on a heart valve replacement method developed by Colibri Heart Valve.

DeepQure has secured approval from South Korea's MFDS for the trial of its HyperQure, aimed at treating atrial fibrillation (AF).

RadNet's subsidiary DeepHealth has concluded the previously announced acquisition of iCAD in a deal valued at $103m.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Saluda Medical has announced the full US commercial launch of its EVA sensing technology intended for scanning and analysing the spinal cord.

Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a trial that is underway at EU sites.

Medtronic has announced the first subject enrolment in the PELE trial, aiming to assess the Onyx liquid embolic system (LES).

The medical device industry faces being pulled into a broader contest over control, sovereignty and industrial self-sufficiency.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software.

3D printing medical devices: industry unlocks new possibilities 3D printing in the medical device space is on the rise, though challenges remain.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.